Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANALOG DEVICES INCADI · Entity 591 | Director | March 11, 2026 | March 12, 2026 |
| NEOGEN CORPNEOG · Entity 4338 | Director | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANALOG DEVICES INC
Report date March 11, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Comm Stock - $.16-2/3 valueSEC Table I · non-derivative | Direct | 2,325 |
Reported balance
After 2026-03-11 transaction · row 1
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 747 · Balance 2,325 F1: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 11, 2027 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company. |
| Comm Stock - $.16-2/3 valueSEC Table I · non-derivative | IndirectBy Spouse | 50 |
Reported balance
Holding disclosure · report date 2026-03-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 50 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 11, 2027 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company.
NEOGEN CORP
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 11,834 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 9,804 · Balance 11,834 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 · Expires 2036-10-01 | Direct | 20,558 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Grant · Acquired 20,558 · Balance 20,558 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date February 28, 2025 · Filed March 05, 2025
Section 16 reporting ended · disclosed 2025-03-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 74,381 |
Ending reported balance
After 2025-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-28 · Tax withholding · Disposed 7,313 · Balance 75,330 Row 2 · 2025-03-03 · Sale · Disposed 949 · Balance 74,381 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 5, 2019 22:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007238 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,448 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.